Presentations on sickle cell disease (SCD) at the European Hematology Association (EHA) Virtual Congress 2021 spotlighted disease-causing mechanisms, hallmark symptoms, and commonly associated complications. Analysis and discussion focused on traditional therapies such as blood transfusions, haematopoietic stem cell transplantation, and hydroxyurea, whilst also highlighting the promise of a new generation of treatments: gene therapies. Gene addition, gene editing, and gene silencing, though all in the early stages of development, hold exciting potential for patients with SCD.
EMJ Hematology 9 [Supplement 6] . 2021